PHATPhathom Pharmaceuticals, Inc.
$7.12-34% 1Y
$7.12
$6.7252 weeks$18.08
The financials
Phathom Pharmaceuticals, Inc. by the numbers
Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $74M in Q2 2026 (quarter ended Jun 30, 2026), up 88% from the same quarter a year earlier. That came with a gross margin of 80% and net loss of $18M. For the full year FY2025, revenue was $175M (+217% year on year) and net income −$221M. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $74M | $40M | +88% |
| Gross profit | $59M | $34M | +72% |
| Operating income | −$4.0M | −$60M | n/a |
| Net income | −$18M | −$76M | n/a |
| Diluted EPS | −$0.21 | −$1.05 | n/a |